CYH
Community Health Systems, Inc.
CYH's fundamentals are weak and it looks expensive: trading at 8.2x earnings, about four times its usual 2.1x. Its downside scenario is about eight times its upside.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CYH Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Weak |
CYH's profitability is currently stable, but its revenue, cash flow and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CYH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1.3x | $0.35 | -84% |
| Fair | 2x | $0.55 | -75% |
| Expensive | 4.4x | $1.18 | -47% |
| Current | 8.2x | $2.21 | — |
Historical ranges are pointers, not guarantees.
CYH's PE is in its expensive range at 8.2x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CYH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Stable | |
| Limited | |
| Low |
Analysts expect CYH's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over CYH on the outlook, with more favorable revenue expectations.
CYH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.27 | -89% |
| Q2 2026 | $1.86 | +$3.35 |
| Q1 2026 | $3.44 | +$7.12 |
| Q4 2025 | $3.77 | +$7.67 |
| Q3 2025 | $2.42 | +$5.43 |
| Q2 2025 | -$1.49 | -$0.74 |
| Q1 2025 | -$3.68 | -$2.74 |
| Q4 2024 | -$3.90 | -$2.88 |
CYH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CYH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8B | -11% |
| Q2 2026 | $2.8B | -9.8% |
| Q1 2026 | $3B | -6.1% |
| Q4 2025 | $3.1B | -4.9% |
| Q3 2025 | $3.1B | -0.1% |
| Q2 2025 | $3.1B | -0.2% |
| Q1 2025 | $3.2B | +0.6% |
| Q4 2024 | $3.3B | +2.6% |
CYH's revenue has slid since its 2019 peak: $2.8B last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.3% | -2.6 points |
| Q2 2026 | 14% | -2.6 points |
| Q1 2026 | 9.5% | +0.5 points |
| Q4 2025 | 14% | +6 points |
| Q3 2025 | 7.9% | +15 points |
| Q2 2025 | 16% | +8.8 points |
| Q1 2025 | 9% | +1.6 points |
| Q4 2024 | 8.5% | -1.8 points |
CYH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CYH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CYH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $67M | +1575% |
| Q2 2026 | $12M | +$15M |
| Q1 2026 | -$373M | -1166% |
| Q4 2025 | $172M | +61% |
| Q3 2025 | $4M | +$7M |
| Q2 2025 | -$3M | -123% |
| Q1 2025 | $35M | +1067% |
| Q4 2024 | $107M | +$127M |
CYH's free cash flow was −$122M over the past year, against $143M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CYH on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -963K shares |
| 1 year | +0.3% | +355K shares |
| 3 years | +3.7% | +4.8M shares |
| 5 years | +3.6% | +4.7M shares |
| Available history | +19% | +21.6M shares |
CYH has 136M diluted shares, about the same as a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CYH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CYH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.5x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 4.9x | High |
| Q4 2025 | 5.3x | High |
| Q3 2025 | 5.9x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 10.2x | High |
| Q4 2024 | 11.1x | High |
CYH's net debt is about 5.5 years of its operating earnings (EBITDA), down from 5.9 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CYH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.4 | Neutral |
| Stochastic | 19.0 | Oversold |
CYH's weekly RSI is 34 (neutral) and its Stochastic is 19 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CYH PE vs Healthcare Sector
| Metric | CYH | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 92 | 29 | 63 pts above |
CYH is trading at 8.2x earnings, a 68% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CYH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.63 | 16% below |
| 20 week MA | $2.90 | 24% below |
| 50 week MA | $3.03 | 27% below |
| 100 week MA | $3.09 | 28% below |
| 200 week MA | $3.55 | 38% below |
CYH is in a downtrend: it's below all five of its weekly moving averages, and 38% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CYH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.77 | $7.67 | +177% |
| 2021 | $7.67 | $13.3 | +73% |
| 2022 | $13.3 | $3.88 | -71% |
| 2023 | $3.88 | $3.13 | -19% |
| 2024 | $3.13 | $3.03 | -3.2% |
| 2025 | $3.03 | $3.23 | +6.6% |
| 2026 YTD | $3.23 | $2.21 | -32% |
CYH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.